Volume 5, Number 11, Supplement 18 (November 2008)

Current Clinical Trials

1

AMG 386 plus sorafenib in metastatic renal cell carcinoma

Brian I. Rini, MD

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

Renal cell carcinoma (RCC) is a rare disease but has been increasing in incidence and is still difficult to treat. Initial results with new targeted therapies indicate an improved response rate and a prolonged progression-free survival (PFS) compared with cytokine-containing therapeutic approaches. Based on the rationale derived from preclinical data of enhanced antitumor effect in combination with vascular endothelial growth factor inhibition, a randomized phase II trial of sorafenib monotherapy versus sorafenib with one of two doses of the investigational angiogenesis inhibitor AMG 386 is ongoing in previously untreated metastatic RCC patients. Patients participating in the study will be evaluated for PFS.

abstract

full text

223 kb

© 2008 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.